[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100451700":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":17,"responsibleParty":30,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Asian Institute of Gastroenterology, India","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Biomarkers","Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).",[13],{"name":14,"affiliation":15,"role":16},"Mohan Dr Ramchandani, MBBS MD","Asian Institute of Gastroenterology","STUDY_DIRECTOR",[18],{"facility":15,"status":7,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Hyderabad","Telangana","500082","India","IN",{"type":25,"coordinates":26},"Point",[27,28],78.45636,17.38405,{"lat":28,"lon":27},{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Mohan Ramchandani","Clinical Professor","100451700","role-of-urinary-biomarker-neutrophil-gelatinase-associated-lipocalcin-ngal-in-early-prediction-of-aki-in-cirrhosis-of-liver-100451700",false,"NCT05161910","ROLE OF URINARY BIOMARKER NEUTROPHIL GELATINASE ASSOCIATED LIPOCALCIN (NGAL) IN EARLY PREDICTION OF AKI IN CIRRHOSIS OF LIVER","Urinary Biomarker Neutrophil Gelatinase Associated Lipocalcin (NGAL) in Early Prediction of AKI in Cirrhosis of Liver","NGAL","Inclusion Criteria:\n\n* Cirrhosis diagnosis by combination of clinical, laboratorial, endoscopic and imaging\n* Age over 18 years old\n* Acute kidney injury (defined by ICA-AKI criteria)\n* Agreement to participate in the study\n\nExclusion Criteria:\n\n* Shock\u002FCCF\n* Age less than 18yrs •\n* Underwent renal replacement therapy within the last 6 week prior to evaluation\n* Prior kidney or liver transplantation\n* Confirmed pregnancy\n* Established CKD\n* Congestive cardiac failure\n* Patients who have taken diuretics in the last 48 hours","ALL","18 Years","75 Years",{"count":46,"type":47},120,"ACTUAL","OBSERVATIONAL","Kidney dysfunction is a complex and common event in patients with liver cirrhosis. Although novel treatments have shown some promising results , acute kidney injury remains a major complication of decompensated liver cirrhosis with high morbidity and mortality rates . AKI occurs in up to 19-20% of hospitalized patients with liver cirrhosis and among the most frequent causes are prerenal azotemia (PRA), hepatorenal syndrome and acute tubular necrosis , with prevalence rates estimated around 68%, 25%, and 33%, respectively.\n\nThe introduction and widespread use of diagnostic criteria of AKI in the area of cirrhosis has contributed to an increased awareness and earlier detection of AKI. However, some important problems remain. One of the main issues is the differential diagnosis of AKI, particularly between acute tubular necrosis (ATN) and hepatorenal syndrome (HRS-AKI). This is important because treatment is different; renal replacement therapy (RRT) is used for the former, and vasoconstrictors and albumin are used for the latter.",[51],"Renal Failure","COMPLETED","2021-12-23",{"date":55,"type":47},"2021-12-29",{"date":57,"type":47},"2020-03-01",{"date":59,"type":47},"2021-08-30",{"name":5,"class":6},1]